p27Kip11 is required for PTEN-induced G1 growth arrest

Cancer Research

Volumn 61, Issue 5, 2001, Pages 2105-2111

  Gottschalk, Alexander R ^a   Basila, Daniel ^a   Wong, Michelle ^b   Dean, Nicholas M ^c   Brandts, Christian H ^b   Stokoe, David ^b   Haas Kogan, Daphne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN A; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; MUTANT PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CDK2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHROMONE DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; MORPHOLINE DERIVATIVE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DEPHOSPHORYLATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WART VIRUS; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLIOMA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CHROMONES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; G1 PHASE; GLIOMA; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MORPHOLINES; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0035263289     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Superfractionated radiotherapy in grade III, IV intracranial gliomas
2. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
3. In vitro intrinsic radiation sensitivity of glioblastoma multiforme
4. The role of phosphoinositide 3-kinase lipid products in cell function
5. Mechanisms consequences of activation of protein kinase B/Akt
6. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region
7. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families
8. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily
9. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation
10. Phosphoinositide 3-kinase and the regulation of cell growth
11. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase
12. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma
13. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
14. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
15. PIK3CA is implicated as an oncogene in ovarian cancer
16. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
17. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
18. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
19. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
20. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
21. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC
22. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
23. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma
24. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells
25. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells
26. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes
27. PTEN turnout suppressor is linked to the cell cycle control through the retinoblastoma protein
28. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway
29. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130
30. A simplified system for generating recombinant adenoviruses
31. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression
32. Adenovirus endocytosis via α(v) integrins requires phosphoinositide-3-OH kinase
33. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway
34. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma
35. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
36. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
37. Association of human papillomavirus types 16 and 18 E6 proteins with p53
38. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle
39. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (GO state) in fibroblasts
40. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
41. Translational control of p27Kip1 accumulation during the cell cycle
42. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest
43. Cyclin E-CDK2 is a regulator of p27Kip1
44. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27
45. Transforming growth factor β targeted inactivation of cyclin E:Cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of cdk2 activating kinase activity
46. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
47. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1)
48. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
49. The murine gene p27Kip1 is haplo-insufficient for tumour suppression
50. p27Kip1 deletions in childhood acute lymphoblastic leukemia
51. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2
52. Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1
53. New insights into the tumor suppression function of p27(kip1)
54. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
55. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
56. Loss of PTEN facilitates HIF-1-mediated gene expression